Velizar Shivarov

Dr. Velizar Shivarov

Medical University Pleven, Pleven, Bulgaria
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Leukemia Research
Verified
Journal Article
Closed access
VSVelizar Shivarov
Velizar Shivarov
RGRalitza Gueorguieva
Ralitza Gueorguieva
ASAngel Stoimenov
Angel Stoimenov
RTRamon Tiu
Ramon Tiu

21 February 2014 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
VSVelizar Shivarov
Velizar Shivarov
MIM Ivanova
M Ivanova
RTR V Tiu
R V Tiu
Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca2+: some mechanistic and therapeutic implications

28 October 2020 in International Journal of Immunogenetics
Verified
Journal Article
Open access
PDF file
MIMilena Ivanova
Milena Ivanova
VSVelizar Shivarov
Velizar Shivarov
The implementation of the immune checkpoint blockade as a therapeutic option in contemporary oncology is one of the significant immunological achievements in the last century. Constantly accumulating evidence suggests that the response to immune checkpoint inhibitors (ICIs) is not universal. Therefore, it is critical to identify determinants for response, resistance and adverse effects of immune checkpoint therapy that could be developed as prognostic and predictive markers. Recent large scale analyses of cancer genome data revealed the key role of HLA class I and class II molecules in cancer immunoediting, and it appears that HLA diversity can predict response to ICIs. In the present review, we summarize the emerging data on the role of HLA germline variations as a marker for response to ICIs.

2 March 2025 in Immuno
Verified
Journal Article
Open access
PDF file
EBElitsa Ivanova Boneva
Elitsa Ivanova Boneva
VSVelizar Shivarov
Velizar Shivarov
MIMilena Ivanova
Milena Ivanova
The immune system’s ability to detect and eliminate transformed cells is a critical factor in suppressing cancer development. However, immune surveillance in tumors is often disrupted by various immune escape mechanisms, many of which remain poorly understood. The Natural Killer Group 2D (NKG2D) receptor is an activating receptor expressed on natural killer (NK) cells and cytotoxic T lymphocytes. It can recognize and bind with varying affinities to a wide range of structurally diverse ligands, including MHC class I chain-related proteins A and B (MICA and MICB) and members of the ULBP family (ULBP1-6). The expression of these ligands plays a crucial role in immune antitumor responses and cancer immunoevasion mechanisms. Some evidence suggests that functional polymorphisms in the NKG2D receptor and the genes encoding its ligands significantly influence HLA-independent cancer immunosurveillance. Consequently, the NKG2D-NKG2D ligands (NKG2DLs) axis represents a promising target for developing novel therapeutic strategies. This review aims to provide a general overview of the role of NKG2D and its ligands in various malignancies and explore their potential in advancing personalized cancer treatment protocols.

1 September 2019 in Human Immunology
Verified
Journal Article
Closed access
MIMilena Ivanova
Milena Ivanova
LCLisa E. Creary
Lisa E. Creary
BHBushra Al Hadra
Bushra Al Hadra
TLTsvetelin Lukanov
Tsvetelin Lukanov
MMMichela Mazzocco
Michela Mazzocco
ENElissaveta Naumova
Elissaveta Naumova

1 December 2020 in Experimental Hematology
Verified
Journal Article
Closed access
MIMilena Ivanova
Milena Ivanova
GTGergana Tsvetkova
Gergana Tsvetkova
TLTsvetelin Lukanov
Tsvetelin Lukanov
ASAngel Stoimenov
Angel Stoimenov
EHEvgueniy Hadjiev
Evgueniy Hadjiev
VSVelizar Shivarov
Velizar Shivarov